Blockade of P2X-purinoceptors by Trypan Blue in Rat Vas Deferens

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1994 Oct 1

PMID 7834182

Citations 8

Authors

R Bultmann

M Trendelenburg

K Starke

Affiliations

Soon will be listed here.

Abstract

1. The possibility of an antagonist effect of trypan blue at P2X-purinoceptors was studied in rat vas deferens. 2. Trypan blue (3.2-320 microM) shifted the concentration-contraction response curve of alpha,beta-methylene ATP (alpha,beta-MeATP) to the right and simultaneously increased the maximum of the curve by up to 40%. The Schild plot had a slope not significantly different from unity and yielded a pA2 value of 5.3 (KB 4.9 microM). 3. Suramin (32 microM) also shifted the concentration-response curve of alpha,beta-MeATP to the right, KB 2.6 microM, and increased the maximum by 31%. In the presence of suramin (32 microM), trypan blue (32 microM) did not change the concentration-response curve of alpha,beta-MeATP. 4. 1-Amino-8-naphthol-3, 6-disulphonate (H-acid) 10 mM, the sulphonic acid-carrying moiety of trypan blue, shifted the concentration-response curve of alpha,beta-MeATP to the right, KB 1.4 mM, and increased the maximum by 33%. 5. Trypan blue did not change contractions elicited by high K+ and noradrenaline. 6. Trypan blue attenuated the purinergic component of neurogenic contractions, IC50 44.9 microM, but did not change the adrenergic component. 7. It is concluded that trypan blue blocks P2X-purinoceptors in rat vas deferens. The increase of the maximum of the alpha,beta-MeATP concentration-response curve is similar in mechanism to the increase produced by suramin.

Citing Articles

P2X receptors as drug targets.

North R, Jarvis M Mol Pharmacol. 2012; 83(4):759-69.

PMID: 23253448 PMC: 3608433. DOI: 10.1124/mol.112.083758.

New insights on P2X purinoceptors.

Humphrey P, Buell G, Kennedy I, Khakh B, Michel A, Surprenant A Naunyn Schmiedebergs Arch Pharmacol. 1995; 352(6):585-96.

PMID: 9053729 DOI: 10.1007/BF00171316.

Evaluation of P2-purinoceptor antagonists at two relaxation-mediating P2-purinoceptors in guinea-pig taenia coli.

Bultmann R, Dudeck O, Starke K Naunyn Schmiedebergs Arch Pharmacol. 1996; 353(4):445-51.

PMID: 8935712 DOI: 10.1007/BF00261442.

P2-purinoceptor antagonists: III. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to suramin.

Bultmann R, Wittenburg H, Pause B, KURZ G, Nickel P, Starke K Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(4):498-504.

PMID: 8897454 DOI: 10.1007/BF00168442.

P2-purinoceptor antagonists: II. Blockade of P2-purinoceptor subtypes and ecto-nucleotidases by compounds related to Evans blue and trypan blue.

Wittenburg H, Bultmann R, Pause B, Ganter C, KURZ G, Starke K Naunyn Schmiedebergs Arch Pharmacol. 1996; 354(4):491-7.

PMID: 8897453 DOI: 10.1007/BF00168441.

References

von Kugelgen I, Bultmann R, Starke K . Interaction of adenine nucleotides, UTP and suramin in mouse vas deferens: suramin-sensitive and suramin-insensitive components in the contractile effect of ATP. Naunyn Schmiedebergs Arch Pharmacol. 1990; 342(2):198-205. DOI: 10.1007/BF00166965. View

Kennedy C . P1- and P2-purinoceptor subtypes--an update. Arch Int Pharmacodyn Ther. 1990; 303:30-50. View

BLAKELEY A, Brockbank J, Kelly S, Petersen S . Effects of suramin on the concentration--response relationship of alpha, beta-methylene ATP on the mouse vas deferens. J Auton Pharmacol. 1991; 11(1):45-9. DOI: 10.1111/j.1474-8673.1991.tb00243.x. View

Lambrecht G, Friebe T, Grimm U, Windscheif U, Bungardt E, Hildebrandt C . PPADS, a novel functionally selective antagonist of P2 purinoceptor-mediated responses. Eur J Pharmacol. 1992; 217(2-3):217-9. DOI: 10.1016/0014-2999(92)90877-7. View

Boland B, Himpens B, Vincent M, Gillis J, Casteels R . ATP activates P2x-contracting and P2y-relaxing purinoceptors in the smooth muscle of mouse vas deferens. Br J Pharmacol. 1992; 107(4):1152-8. PMC: 1907937. DOI: 10.1111/j.1476-5381.1992.tb13422.x. View

Soltoff S, McMillian M, Talamo B, Cantley L . Blockade of ATP binding site of P2 purinoceptors in rat parotid acinar cells by isothiocyanate compounds. Biochem Pharmacol. 1993; 45(9):1936-40. DOI: 10.1016/0006-2952(93)90455-6. View

Bultmann R, Szabo B, Starke K . Inhibition by ethanol of contractions of rat vas deferens: no evidence for selective blockade of P2X-purinoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1993; 347(5):527-33. DOI: 10.1007/BF00166746. View

Fuder H, Muth U . ATP and endogenous agonists inhibit evoked [3H]-noradrenaline release in rat iris via A1 and P2y-like purinoceptors. Naunyn Schmiedebergs Arch Pharmacol. 1993; 348(4):352-7. DOI: 10.1007/BF00171333. View

Trezise D, Kennedy I, Humphrey P . Characterization of purinoceptors mediating depolarization of rat isolated vagus nerve. Br J Pharmacol. 1993; 110(3):1055-60. PMC: 2175797. DOI: 10.1111/j.1476-5381.1993.tb13920.x. View

10.

Venkova K, Krier J . Stimulation of lumbar sympathetic nerves evokes contractions of cat colon circular muscle mediated by ATP and noradrenaline. Br J Pharmacol. 1993; 110(3):1260-70. PMC: 2175786. DOI: 10.1111/j.1476-5381.1993.tb13951.x. View

11.

Ziganshin A, Hoyle C, Bo X, Lambrecht G, Mutschler E, Baumert H . PPADS selectively antagonizes P2X-purinoceptor-mediated responses in the rabbit urinary bladder. Br J Pharmacol. 1993; 110(4):1491-5. PMC: 2175839. DOI: 10.1111/j.1476-5381.1993.tb13990.x. View

12.

Bultmann R, Starke K . Evans blue blocks P2X-purinoceptors in rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1993; 348(6):684-7. DOI: 10.1007/BF00167248. View

13.

Bultmann R, Starke K . P2-purinoceptor antagonists discriminate three contraction-mediating receptors for ATP in rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1994; 349(1):74-80. DOI: 10.1007/BF00178209. View

14.

von Kugelgen I, Kurz K, Starke K . P2-purinoceptor-mediated autoinhibition of sympathetic transmitter release in mouse and rat vas deferens. Naunyn Schmiedebergs Arch Pharmacol. 1994; 349(2):125-32. DOI: 10.1007/BF00169828. View

15.

ARUNLAKSHANA O, SCHILD H . Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959; 14(1):48-58. PMC: 1481829. DOI: 10.1111/j.1476-5381.1959.tb00928.x. View

16.

Mallard N, Marshall R, Sithers A, Spriggs B . Suramin: a selective inhibitor of purinergic neurotransmission in the rat isolated vas deferens. Eur J Pharmacol. 1992; 220(1):1-10. DOI: 10.1016/0014-2999(92)90004-n. View

17.

Motulsky H, Ransnas L . Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J. 1987; 1(5):365-74. View

18.

Dunn P, BLAKELEY A . Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens. Br J Pharmacol. 1988; 93(2):243-5. PMC: 1853806. DOI: 10.1111/j.1476-5381.1988.tb11427.x. View

19.

McMillian M, Soltoff S, Lechleiter J, Cantley L, Talamo B . Extracellular ATP increases free cytosolic calcium in rat parotid acinar cells. Differences from phospholipase C-linked receptor agonists. Biochem J. 1988; 255(1):291-300. PMC: 1135222. View

20.

Soltoff S, McMillian M, Talamo B . Coomassie Brilliant Blue G is a more potent antagonist of P2 purinergic responses than Reactive Blue 2 (Cibacron Blue 3GA) in rat parotid acinar cells. Biochem Biophys Res Commun. 1989; 165(3):1279-85. DOI: 10.1016/0006-291x(89)92741-1. View